Lunit Highlights the Effectiveness of AI in Predicting Cancer Treatment Outcomes - Findings to be Presented at ASCO GI 2023
- Written by PR Newswire
![]() |
- Lunit to present two abstracts featuring Lunit SCOPE IO, the company's AI biomarker for immune phenotyping
- Lunit's presentations this year will highlight the effectiveness of Lunit SCOPE IO as a biomarker to predict treatment outcomes in liver and colon cancer
SEOUL, South Korea, Jan. 18, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ) today announced...